EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Current Status and the Need for CFTR Modulator Therapy in Cystic Fibrosis Patients in Mainland China: A Case Report and Literature Review

Yuxiao Sun, Junbao Du iD, Lifen Gong, Jialiang Wang, Jing Zhang, Yaqin Xu, Lei Wang, Ziwei Zhang iD, Hang Cheng iD

Pediatric Pulmonology · 2026

DOI: 10.1002/ppul.71590 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Pulmonology, 2026. Verfasst von Yuxiao Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Aminophenols, Benzodioxoles, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Zhejiang University, Jilin Provincial Key Laboratory of Biotherapy, Scientific Research Project of Education Department of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cystic fibrosis (CF) is a life‐threatening genetic disorder characterized by dysfunctional mucus production, leading to severe respiratory and digestive complications. CF transmembrane conductance regulator (CFTR) modulators are highly effective targeted therapies for CF; however, they are not yet available in mainland China, resulting in no published reports on their use in Chinese CF patients.

Objective

To report a case of CF patient with compound heterozygous CFTR mutations (c.2909G〉A/c.2491‐2A〉G) treated withelexacaftor/tezacaftor/ivacaftor (ETI) in China and summarize the diagnosis and treatment status based on a literature review, exploring the potential efficacy of CFTR modulators in the Chinese population.

Methods

Case Report: Clinical data and treatment response of a CF patient receiving ETI were analyzed. Literature Review: PubMed, CNKI, and Wanfang were searched (Jan 2010‐Aug 2025) to identify CF cases reported in China. A total of 71 cases were included for analysis of diagnosis, treatment, and outcomes.

Results

Case Outcome: The patient showed significant clinical improvement within 2 weeks after ETI initiation. Literature Analysis: The 71 cases demonstrated heterogeneity in diagnosis and treatment, with most relying on supportive therapies and lacking gene‐targeted interventions. Status Summary: CF diagnosis rates are low in China, genetic testing is insufficient, and CFTR modulator accessibility is limited.

Conclusion

This study presents the first report of CFTR modulator efficacy in a Chinese patient, indicating potential treatment benefits. It underscores the urgent need to improve CF awareness, establish a CF genetic mutation database, and expedite CFTR modulator approval/access to promote personalized treatment and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminophenolsBenzodioxolesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorIndolesQuinolonesThiophenesHumansChinaDrug CombinationsMutationTreatment Outcome

Stichwörter der Autor:innen

CFTR modulator therapyChinese populationcystic fibrosis

Substanzen

AminophenolsBenzodioxolesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsIndolesQuinolonestezacaftor, ivacaftor drug combinationThiophenes

Autor:innen und Institutionen

  • Department of Pediatrics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

ORCID-Profile: Junbao Du, Ziwei Zhang, Hang Cheng

Förderung

  • Zhejiang University
  • Jilin Provincial Key Laboratory of Biotherapy
  • Scientific Research Project of Education Department of Jilin Province

Zitieren

APA

Sun, Y., Du, J., Gong, L., Wang, J., Zhang, J., Xu, Y., Wang, L., Zhang, Z., & Cheng, H. (2026). Current Status and the Need for CFTR Modulator Therapy in Cystic Fibrosis Patients in Mainland China: A Case Report and Literature Review. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71590

Vancouver

Sun Y, Du J, Gong L, Wang J, Zhang J, Xu Y, et al. Current Status and the Need for CFTR Modulator Therapy in Cystic Fibrosis Patients in Mainland China: A Case Report and Literature Review. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71590

BibTeX
@article{Sun2026,
  author = {Sun, Yuxiao and Du, Junbao and Gong, Lifen and Wang, Jialiang and Zhang, Jing and Xu, Yaqin and Wang, Lei and Zhang, Ziwei and Cheng, Hang},
  title = {Current Status and the Need for CFTR Modulator Therapy in Cystic Fibrosis Patients in Mainland China: A Case Report and Literature Review},
  journal = {Pediatric Pulmonology},
  year = {2026},
  doi = {10.1002/ppul.71590}
}
Kostenlos starten →